Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review

Immune checkpoint inhibitors (ICIs), which target CTLA-4 or PD-(L)1 molecules, have shown impressive therapeutic results. Durable responses, however, are only observed in a segment of the patient population and must be offset against severe off-target immune toxicity and high costs. This calls for b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouwerkerk, Wouter, van den Berg, Mirjam, van der Niet, Sanne, Limpens, Jacqueline, Luiten, Rosalie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727956/
https://www.ncbi.nlm.nih.gov/pubmed/30855527
http://dx.doi.org/10.1097/CMR.0000000000000589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727956/
https://www.ncbi.nlm.nih.gov/pubmed/30855527
http://dx.doi.org/10.1097/CMR.0000000000000589

Ejemplares similares